33 results about "Metal Chelator" patented technology

The present disclosure relates to the use of a metal chelator to treat an exposed photoresist film. In particular embodiments, the metal chelator is employed to remove an interfacial area that is disposed between exposed and unexposed areas or disposed within an exposed area, thereby enhancing patterning quality.

A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F / 18F exchange or a precursor thereof; and optionally a cell-targeting domain.

A microorganism engineered to: produce or overproduce auxin; reduce the production of ethylene; produce or overproduce one or more metal chelator molecules; and / or reduce or knockout the production of

Metal chelation compounds and associated coordination complexes are provided. In one aspect, this disclosure provides for a metal chelation compound, the compound having the general structure: D-L-T, wherein D is deferasirox or a derivative thereof, T is triapine or a derivative thereof, and L is a linking group and is a bond, C1-C10 alkyl, C2-C10 alkenyl, or —(C0-C3 alkyl)-R—(C0-C3 alkyl)-, wherein R is aryl, cycloalkyl, or polyethylene glycol.

The application provides a chemical detachable hydrogel electrode for physiological electrical measurement, a use method thereof, and the electrode comprises a flexible base layer, a flexible packaging layer, a flexible electrode array layer integrated with internal circuits and one or more electrode points, a hydrogel base layer, a detachable hydrogel interface layer, and separately stored polymer solution, metal ion anchoring solution and metal chelating agent solution; the flexible electrode array layer is arranged in a flexible frame body formed by the flexible base layer and the flexible packaging layer, the electrode points extend out of the flexible frame body, the hydrogel base layer covers the electrode points, the detachable hydrogel interface layer is detachably arranged on the hydrogel base layer, and the combination and detachment with the hydrogel base layer are realized through the polymer solution, the metal ion anchoring solution and the metal chelating agent solution. The electrode can realize the detachable hydrogel interface through chemical solution immersion, realize the repeated use of the electrode, and reduce the cross-infection risk.

The present invention relates to the technical field of biological material preservation, and particularly discloses an RNA preservation tube, which comprises: an amino acid component selected from at least one of glycine and a derivative thereof; the EDTA metal chelating agent is selected from at least one of EDTA alkali metal salts and hydrates thereof; a preservative component; optionally comprising a pH indicator; the storage tube is provided with a sealed cavity for storing an RNA solution, and the volume of the cavity is 1-20ml; through combination of a glycine-EDTA synergistic buffer system and an imidazolidinyl urea preservative, long-acting stable preservation of an RNA sample in an extreme environment is realized, metal ions can be dynamically chelated and the pH value is maintained in a range of 6.8-7.5 through a specific ratio of glycine to EDTA salt, a multi-protection mechanism is formed by combining a tube wall nucleic acid adsorption inhibition treatment technology, and the RNA sample can be stably preserved in the extreme environment through the combination of the glycine-EDTA synergistic buffer system and the imidazolidinyl urea preservative. And the loss caused by RNA enzyme activity, acid-base degradation and physical adsorption is effectively blocked, and the product is especially suitable for high-temperature transportation or long-term normal-temperature storage scenes.

The present invention relates to the field of cell preservation fluid, and provides a cell preservation fluid and a red blood cell simulant, and a preparation method and application thereof. The cell preservation fluid comprises a polyphenol compound, a buffer system, a metal chelator, a nutrient, a metabolic regulator, mannitol, a poloxamer, and an optional preservative. The preparation method of the red blood cell simulant comprises the following steps: taking venous blood from a mammal and purifying it to obtain red blood cells; then fixing the obtained red blood cells with a fixative; and then dispersing the red blood cells obtained by the fixation in the cell preservation fluid of the present invention. The cell preservation fluid of the present invention is beneficial to improving the stability of red blood cells and maintaining good uniformity of red blood cells; the red blood cells in the red blood cell simulant of the present invention have good opening stability, thermal stability, and long-term stability, and the coefficient of variation of the red blood cells is low, and the product batch reproducibility is good.

The present invention discloses a PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group and its preparation, which belongs to the technical fields of radiopharmaceuticals and medical imaging. The general formula of the PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group of the present invention is shown in Formula I and Formula II. The present invention is the first to link both a nitroaromatic group and a PSMA-targeting group to a metal chelator (such as HBED-CC, DOTA, DOTA(GA)2, NOTA, AAZTA, etc.) and to target a radiometal nuclide, e.g. 68 Ga, 18 F-AlF, 177 Lu, 90 Y, 44 Sc, 225 Ac, 212 Pb, 213 The radioactive metal marker is labeled with Bi, etc. The synergistic effect of the nitroaromatic heterocyclic group in vivo is expected to increase the uptake of the radioactive metal marker by prostate cancer, promoting metabolism in non-target organs and improving the therapeutic efficacy of radiopharmaceuticals against tumors. JPEG2026508753000106.jpg2835JPEG2026508753000107.jpg2145 (wherein the R1 and R2 groups are nitroaromatic heterocyclic groups; L2 is a linking group between the R1 group and L1, where L1 is a linking group between the chelator and the structure PSMA targeting structure; L4 is a linking group between the R2 group and L3, where L3 is a linking group between the chelator and the structure PSMA targeting structure; and ChelatoR1 and ChelatoR2 are chelators or chelating structures.)

Provided herein are methods of treating SSTR + cancer using radiopharmaceutical compositions. The radiopharmaceutical compositions may include one or more stabilizers, an aqueous vehicle, and a conjugate containing a targeting ligand and a radionuclide bound to a metal chelating agent. The targeting ligand may be a small molecule compound or peptide, such as a monocyclic peptide. The targeting ligand may be configured to bind to a tumor target. The stabilizers may include radiolytic stabilizers, free metal chelating agents, and / or pH stabilizers. Also provided herein are methods of making the radiopharmaceutical compositions and methods of treating cancer by administering the radiopharmaceutical compositions.

Disclosed is a method for preserving high molecular weight DNA in biological tissue, comprising contacting for a period of time at a temperature the biological tissue with an aqueous solution comprising a compound having the structure:

Provided herein are a variety of metal chelators as well as methods of use thereof.

The present invention belongs to the technical field of radiopharmaceutical chemistry and nuclear medicine diagnosis and treatment. Disclosed are a compound for dual targeting of a tumor cell, a preparation method therefor and the use thereof. The compound for dual targeting of a tumor cell has general formulas as represented by formula (I) and formula (II), wherein L1 and L3 are linking groups between a chelator and a PSMA-targeting structure; L2 and L4 are linking groups between the chelator and Peptide1; the Peptide1 and Peptide2 are polypeptide molecules having an SSTR2 targeting property, such as JR11, LM3, LM4, TATE, TOC and NOC; and Chelator1 and Chelator2 are chelators or chelating structures. In the present invention, a PSMA-targeting group and an SSTR2-targeting group are simultaneously linked to a metal chelator (HBED-CC, DOTAGA, DOTA(GA)2, etc.) for the first time for labeling a radioactive metal nuclide such as 68Ga, 18F-AlF, 177Lu, 90Y, 44Sc, 225Ac, 212Pb and 213Bi. The dual targeting function on PSMA and SSTR2 is beneficial to improving the lesion detection rate of neuroendocrine prostate cancer, and achieving more accurate tumor staging and disease prognosis, and is expected to be used for radionuclide targeted therapy.

Provided herein are methods of treating prostate cancer using radiopharmaceuticals. The radiopharmaceuticals compositions can comprise a prostate specific membrane antigen (PSMA) targeting moiety, a metal chelator, and a radionuclide chelated to the metal chelator.

Provided herein are a complex for diagnosing non-alcoholic steatohepatitis, use of the complex, and a contrast agent comprising the complex. The complex for diagnosing non-alcoholic steatohepatitis comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator. The complex is capable of binding to an asialoglycoprotein receptor, so that the complex has potential for use as a radiological diagnostic agent.

The invention discloses a flexible perovskite solar cell based on a metal chelating agent and a preparation method of the flexible perovskite solar cell. The flexible perovskite solar cell comprises a flexible transparent conductive substrate, an electron transport layer, a metal chelating agent molecule modification layer, a perovskite light absorption layer, a hole transport layer and an electrode which are sequentially arranged from bottom to top, wherein the metal chelating agent molecule modification layer adopts any one of EDTA-4Na and EGTA-4Na molecules, Na diffusion of the EDTA-4Na and the EGTA-4Na in the annealing process dopes the electron transport layer to improve the conductivity, and the EDTA-4Na molecules and the EGTA-4Na molecules interact with the perovskite light absorption layer and the electron transport layer to form passivation interface defects to improve the interface adhesion, so that the conductivity of the perovskite light absorption layer is improved. And a long chain of the EGTA-4Na molecule is used for absorbing stress in the bending process. The invention aims to improve the conductivity of the oxide electron transport layer, passivate the defects of the buried interface, improve the adhesion of the buried interface and finally improve the efficiency and stability of the flexible perovskite solar cell by introducing chelating molecule interface modification.

The present invention relates to the field of food preparation technology, specifically a method for inhibiting trans fatty acids in beef tallow hot pot based on enzymatic hydrolysis and synergistic active substances. The steps of the method are: in the process of preparing beef tallow hot pot, enzymatic hydrolysis of beef tallow before frying to reduce the production of isomerized substrates; after frying the beef tallow and raw materials, active substances are added before being taken out of the pot to block the oxidation / isomerization path and complete the inhibition of trans fatty acid production in beef tallow hot pot. The present invention first uses specific lipase to cut off the unsaturated fatty acid chains that are easily isomerized in triglycerides, reducing the isomerized substrates at high temperatures, and then uses a compound antioxidant and a metal chelator to block the free radical chain reaction and the catalytic metal ion (such as #imgabs0#) that promotes isomerization. The two synergistically reduce the generation of TFAs, so that the TFAs reduction rate is ≥60%.

The invention discloses a component liquid capable of improving the combination efficiency of Biotin and SA magnetic beads and a preparation method of the component liquid. The component liquid is mainly composed of a catalyst, other compounds, a surfactant, a metal chelating agent and the like. The component liquid provided by the invention can be applied to the field of detection of chemiluminescence immunodiagnostic reagents, in particular to numerous clinical sample detection items such as nail function, inflammation, hypertension, cytokines, bone metabolism, growth hormone and the like. The method not only can effectively shorten the time required by the reaction process, but also can remarkably amplify the sensitivity of the reagent. The shortening of the reaction time is beneficial to quickly obtaining a detection result in a third-level hospital with a huge sample size, and the method shows remarkable application advantages.

The present invention relates to zwitterionic metal chelators and their use as imaging agents, diagnostic agents, chemical processing agents, and therapeutic agents. These zwitterionic metal chelators have desirable properties of maximizing solubility in aqueous environments, minimizing non-specific interactions, and retaining targeting ability, resulting in improved performance in a variety of medical, agricultural, and chemical processes. In vivo and medical applications, the zwitterionic metal chelators improve signal-to-background ratios and therapeutic windows compared to other metal chelators, while retaining high stability.

The present disclosure provides novel halogenated (e.g., fluorinated) chelators and metal complexes. The disclosed composition can be used in imaging and therapeutic methods, such as in PET for imaging targeted alpha therapies (TATs).

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.

The application relates to the field of chelator preparation, in particular to a high-efficiency metal chelator and a preparation method and application thereof. The preparation method comprises the following preparation steps: (1) dissolving dibutanolamine in anhydrous ethanol, adding carbon disulfide, reacting under a nitrogen atmosphere at 0-5 DEG C for 5-8 h, adjusting the pH to neutral by using a sodium hydroxide aqueous solution, rotary evaporating, and obtaining sodium bis(4-hydroxybutyl) dithiocarbamate; (2) adding 4-[bis(beta-chloroethyl) amino] benzaldehyde, the sodium bis(4-hydroxybutyl) dithiocarbamate in step (1) and a catalyst in anhydrous ethanol, heating and refluxing, removing the anhydrous ethanol under reduced pressure, stirring the obtained solid in pure water, extracting and combining the organic phases, drying the moisture in the organic phases, concentrating, standing for 10-20 h, separating, and obtaining the metal chelator. The metal chelator prepared by the application has good dispersibility and solubility in various solvents, can be coordinated and chelated with heavy metal ions through active functional groups, and forms stable metal chelates.

The present invention relates to an engineered microorganism for use in combination with a plant to increase the uptake of metals from a growth medium. In particular, engineering a microorganism to exploit plant hormonal synthesis, suppress stress response, and produce metal chelators is described.

SOLUTION: The present disclosure relates to use of a metal chelator to treat an exposed photoresist film. In particular embodiments, the metal chelator is employed to remove an interfacial area that is disposed between exposed and unexposed areas or disposed within an exposed area, thereby enhancing patterning quality.SELECTED DRAWING: Figure 2A

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.

Provided herein are methods of treating prostate cancer using radiopharmaceuticals. The radiopharmaceuticals compositions can comprise a prostate specific membrane antigen (PSMA) targeting moiety, a metal chelator, and a radionuclide chelated to the metal chelator.

This application belongs to the field of photodetector technology, and relates to a method for preparing a metal-doped A2BX5 crystal, a thin film thereof, and a photodetector. The method for preparing the metal-doped A2BX5 crystal includes providing a first mixed solution comprising AX, BX2, CX2, and a first solvent; subjecting the first mixed solution to a first heat treatment to obtain a second mixed solution; adding a metal chelating agent to the second mixed solution to obtain a third mixed solution; adding a second solvent to the third mixed solution and performing a second heat treatment to obtain a metal-doped A2BX5 crystal, wherein C is doped in the A2BX5 crystal. The metal chelating agent can bind with B ions in the third mixed solution to form a dynamic supramolecular coordination structure, thereby limiting the nucleation rate of B ions and improving the stability of the metal-doped A2BX5 crystal.

Provided herein are methods of treating prostate cancer using radiopharmaceuticals. The radiopharmaceuticals compositions can comprise a prostate specific membrane antigen (PSMA) targeting moiety, a metal chelator, and a radionuclide chelated to the metal chelator.

Provided herein are peptides and conjugates (e.g., radiopharmaceutical conjugates) having avidity for a somatostatin receptor and uses thereof. The conjugate can comprise a 6-mer peptide, such as a monocyclic 6-mer peptide, a metal chelator, and optionally a linker connecting the peptide to the chelator. The radiopharmaceutical conjugate can further comprise a radionuclide bound to the metal chelator. Further provided herein are methods of preparing the conjugates, and methods of treating cancer by administering the described conjugates to a subject in need thereof.